A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

Study Summary

The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.

Interventions

Study Locations

Facility	City	State	Country
UCSF Benioff Children's Hospital	Oakland	California	United States
Children's Hospital Colorado	Aurora	Colorado	United States
Smilow Cancer Hospital	New Haven	Connecticut	United States
Johns Hopkins All Children's Hospital	St. Petersburg	Florida	United States
Children's Healthcare of Atlanta	Atlanta	Georgia	United States
University of Minnesota	Minneapolis	Minnesota	United States
Columbia University Medical Center - Department of Pediatrics	New York	New York	United States
Columbia University Medical Center	New York	New York	United States
Atrium Health	Charlotte	North Carolina	United States
Cleveland Clinic	Cleveland	Ohio	United States
Nationwide Children's Hospital	Columbus	Ohio	United States
Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	United States
Medical University of South Carolina	Charleston	South Carolina	United States
Tristar Medical Group Children's Specialists/Sarah Cannon Center for Blood Cancers	Nashville	Tennessee	United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center	Dallas	Texas	United States
Cook Children's	Fort Worth	Texas	United States
Ottawa Hospital Research Institute	Ottawa	Ontario	Canada
Princess Margaret Cancer Centre-University Health Network	Toronto	Ontario	Canada

Official Trial Information

View on ClinicalTrials.gov